Cancer Biopsy Market Size By Product (Kits And Consumables, Instruments And Services), By Type (Tissue Biopsies, Liquid Biopsies), & Region For 2024-2031

Published Date: August - 2024 | Publisher: MIR | No of Pages: 320 | Industry: latest updates trending Report | Format: Report available in PDF / Excel Format

View Details Download Sample Ask for Discount Request Customization

Cancer Biopsy Market Size By Product (Kits And Consumables, Instruments And Services), By Type (Tissue Biopsies, Liquid Biopsies), & Region For 2024-2031

Cancer Biopsy Market Valuation 2024-2031

The expanding demand for cancer biopsy technologies is driven by a variety of factors highlighting a growing reliance on these advanced diagnostic techniques to meet changing medical, technological, and efficiency needs. The Cancer Biopsy Market is experiencing consistent growth driven by a wide range of applications in healthcare, pharmaceuticals, biotechnology, and research among others. At the heart of this growing demand is the critical role that biopsy technologies play in enabling early detection, personalised treatment strategies, and improved patient outcomes by enabling the market to surpass a revenue of USD 32.48 Billion valued in 2023 and reach a valuation of around USD 78.14 Billion by 2031.

The growing use of precision medicine and advances in genomic analysis have increased demand for cancer biopsy technology. Biopsy tools have become crucial tools in oncology allowing for reliable tissue sample, genetic profiling, and focused medication selection as precision medicine reshapes cancer care paradigms. Cancer biopsy technologies in particular play an important role in providing clinicians with critical insights into tumour characteristics, guiding treatment decisions, and improving prognostic accuracy by enabling the market to grow at a CAGR of 11.60% from 2024 to 2031. 

Cancer Biopsy Market Definition/Overview

A cancer biopsy is a medical process in which a sample of tissue or cells is removed from a questionable area of the body such as a tumour or abnormal growth, and inspected under a microscope to determine the presence of malignant cells or other abnormalities. The major purpose of a cancer biopsy is to acquire diagnostic information that will aid in determining whether cancer is present, what type of cancer it is, how aggressive it may be, and how to make treatment options. Biopsies can be performed using a variety of techniques depending on the location and size of the suspected tumour such as needle biopsies, surgical biopsies, or endoscopic biopsies.

Cancer biopsies are extremely significant in oncology because to their numerous applications in diagnosis, therapy, and research. They are primarily used to confirm the presence of cancer and elucidate tumour features allowing for more precise treatment planning. This diagnostic application includes staging, prognosis, and treatment methods. Furthermore, biopsy-guided genetic profiling enables personalised treatment selection, demonstrating the use of precision medicine in oncology. Biopsies are also important instruments for assessing treatment response and making modifications for best results. In research, biopsy specimens are critical for revealing tumour biology, finding therapeutic targets, and discovering biomarkers demonstrating their utility in cancer understanding and therapeutic innovation. Biopsies are also important in clinical studies because they provide vital information on therapy efficacy and safety.

The future of cancer biopsies holds the potential for dramatic advances in oncology. Non-invasive and minimally invasive procedures such as liquid biopsies will alleviate patient discomfort and allow for more regular monitoring of tumour progression. The use of artificial intelligence (AI) into biopsy processing will improve diagnostic accuracy and efficiency, which will provide more detailed insights into tumour biology and treatment response. Advances in single-cell analysis technology will reveal new treatment targets and improve patient stratification for personalised medicine. In summary, future cancer biopsies will transform cancer care by allowing for earlier detection, more precise prognosis, and personalised therapeutic approaches.

What's inside a
industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

How the Increasing Technological Developments Drive the Cancer Biopsy Market?

The Cancer Biopsy Market is expanding rapidly due to a number of causes. Technological developments are critical with breakthroughs like liquid biopsies and artificial intelligence (AI) analysis improving the accuracy and capability of biopsy techniques. These developments allow for earlier identification and more exact characterization of tumours, satisfying the increased demand for effective cancer diagnosis. Furthermore, the rising global prevalence of cancer is driving market growth. Ageing populations, lifestyle changes, and environmental variables are all contributing to an increase in cancer incidence demanding strong biopsy-based approaches to patient management. As the cancer burden increases, there is a greater demand for dependable biopsy solutions to aid in prompt diagnosis and treatment decisions.

The drive to personalised therapy is driving up demand for complete DNA profiling via biopsies. Tailoring treatment techniques to individual patient features including tumour molecular profiles is becoming increasingly critical for improving therapeutic success and minimising side effects. This emphasis on personalised medicine highlights the critical importance of biopsies in guiding targeted treatments and immunotherapies. Furthermore, the importance of biopsies in clinical research and medication development cannot be overemphasised. Biopsies give researchers critical insights into tumour biology, therapeutic targets, and treatment response, which drives the development of novel cancer medicines. As biopsies evolve, they will become an increasingly important part in shaping the landscape of cancer care and driving advances in oncology research and therapy.

Will High Cost of Diagnosis Hamper the Cancer Biopsy Market?

The global Cancer Biopsy Market faces substantial growth challenges owing to the high expenses involved with cancer diagnosis. These diagnostic tests are known for their exorbitant costs putting a significant financial pressure on the families of affected patients. This burden is especially significant for the middle-class group which frequently falls beyond the protective canopy of health care coverage. Furthermore, several private insurance carriers are reluctant to include cancer diagnostic charges in their coverage allowing patients to bear the expenditures on their own. As a result, the high cost of cancer detection appears as a strong barrier substantially impeding the widespread adoption of critical cancer screening techniques.

The high cost of cancer diagnosis remains a tremendous barrier to surmount yet, the introduction of medical tourism heralds a paradigm shift in the accessibility and affordability of important healthcare treatments. Medical tourism has the ability to democratize cancer detection by utilizing global connectivity and the power of competition and innovation providing patients with the tools and resources they need to combat this terrible disease. As the healthcare environment changes embracing the transformative power of medical tourism provides a ray of hope for individuals and families navigating the challenging terrain of cancer diagnosis and treatment.

Category – Wise Acumens

How Will the Increasing Demand of for Minimally Invasive Biopsy Treatments Drive the Product Segment?

The growing demand for kits and consumables is likely to have a substantial impact on the type segment of the Cancer Biopsy Market especially in fuelling the expansion of liquid biopsies. As the global use of biopsy procedures grows fuelled by rising cancer rates and a greater emphasis on early diagnosis and personalised care so does the consumption of biopsy-related materials and consumables. Kits and consumables are critical components of both tissue and liquid biopsies serving as tools for sample collection, processing, storage, and analysis.

Biopsy kits are at the forefront of modern medical innovation containing a wide range of necessary tools such as needles, forceps, catheters, and other precise instruments required for executing biopsy procedures. These kits painstakingly created to meet the stringent standards of medical practice, exemplify the intersection of technical innovation and healthcare efficacy. Within their modest confines are the instruments that allow clinicians to navigate the intricate geography of the human body with amazing precision providing previously unfathomable insights.

The consumables needed for liquid biopsies such as blood collection tubes, preservatives, and molecular analysis reagents are especially important because of the unique nature of liquid biopsy samples and the specialised procedures used in their analysis. As a result, rising demand for kits and consumables is expected to fuel expansion in the type sector of the Cancer Biopsy Market with a focus on liquid biopsies as these less intrusive and more accessible techniques gain traction in oncology practice.

How the Increasing Research Operations Testing Drive the Type Segment?

The increasing demand for tissue biopsies is expected to have a substantial impact on the type segment of the Cancer Biopsy Market. As tissue biopsies remain the foundation of cancer diagnosis, their increasing demand reflects the increased requirement for precise and extensive tissue sample to support clinical decision-making. Tissue biopsies are becoming more accurate and useful thanks to technological breakthroughs such as image-guided biopsy procedures and genetic profiling technologies which are boosting their adoption in clinical practice.

This segment’s growth is facilitated by the widespread dissemination of research findings and knowledge sharing within the scientific community. Through publications, conferences, and collaborative partnerships, researchers can exchange ideas, share best practices, and build on each other’s work accelerating the pace of innovation and discovery. This collaborative culture fosters a vibrant ecosystem where ideas can flourish and breakthroughs can be made.

This segment’s expansion can be due to the rigorous research operations that support its development and growth. Researchers verify that products or services fulfil high criteria and effectively address consumer needs by meticulously assessing their safety and efficacy. This commitment to perfection along with a spirit of innovation and cooperation has catapulted the segment to new heights establishing it as the industry’s trusted leader.

Gain access into Cancer Biopsy Market Report Methodology

Country/Region-wise Acumens

Will the Advanced Healthcare Infrastructure Drive the Cancer Biopsy Market in North America?

North America is expected to dominate throughout the forecasted period, North America’s superior healthcare system remains a significant driver driving the region’s cancer biopsy industry. With a vast network of healthcare facilities outfitted with cutting-edge technology and manned by trained personnel, North America provides unprecedented access to cutting-edge biopsy procedures and diagnostic tools. This infrastructure enables healthcare practitioners to perform a wide range of biopsy services including standard tissue samples and new liquid biopsies, thereby facilitating rapid and accurate cancer diagnosis treatment planning, and monitoring. Furthermore, the collaborative environment fostered by prominent research institutions and academic medical centres promotes ongoing innovation in biopsy technology resulting in improvements that improve the quality and efficacy of cancer diagnosis and care.

High standards of care and strong regulatory control in North America ensure the quality and safety of biopsy operations, fostering confidence in both healthcare providers and patients. Healthcare facilities in North America are committed to providing excellent biopsy services with agencies such as the FDA guaranteeing adherence to high quality assurance criteria. This commitment combined with a patient-cantered approach to cancer care and a multidisciplinary approach to treatment emphasises the importance of advanced healthcare infrastructure in driving the growth and evolution of the Cancer Biopsy Market in North America ultimately leading to better patient outcomes and a higher quality of life for cancer patients.

Competitive Landscape

The Cancer Biopsy Market is a dynamic and competitive arena, marked by a diverse array of participants competing for market dominance. These entities are actively seeking to strengthen their foothold by implementing strategic initiatives like partnerships, acquisitions, mergers, and regulatory advocacy. Organizations within this sector are dedicated to enhancing their product portfolios through innovation to cater to the diverse needs of populations across various regions.

Some Prominent Players in the Cancer Biopsy Market include

Illumina, Inc., ANGLE Plc, BD (Becton, Dickinson and Company), Myriad Genetics, Hologic, Inc., Biocept, Inc., Thermo Fisher Scientific, Inc., Danaher, Hoffmann-La Roche Ltd., Lucence Diagnostics Pte. Ltd., and GRAIL, Inc.

Latest Developments

  • In April 2024, a notable development in the Cancer Biopsy Market emerged with the advancement of liquid biopsy techniques for enhanced cancer detection and monitoring.
  • In July 2023, QIAGEN announced the launch of the QIAseq Normalizer Kits, giving researchers a fast, convenient, and cost-effective method to pool different DNA libraries for best-quality results from next-generation sequencing (NGS) runs.
  • In June 2023, QIAGEN announced that its variant interpretation and reporting software, QIAGEN Clinical Insight (QCI) Interpret, is being deployed as a part of a national initiative in Denmark to offer sequencing-based solutions for cancer patients.

Report Scope

REPORT ATTRIBUTESDETAILS
STUDY PERIOD

2018-2031

Growth Rate

CAGR of 11.60%

Base Year for Valuation

2023

HISTORICAL PERIOD

2018-2022

Forecast Period

2024-2031

Quantitative Units

Valur in USD Billion

Report Coverage

Revenue Forecast, Growth Factors, Competitive Landscape, key Players, Segmentation Analysis

Segments Covered
  • Product
  • Type
Region Covered
  • North America
  • Europe
  • Asia Pacific
  • South America
  • Middle East and Africa
Key Players

Illumina, Inc., ANGLE Plc, BD (Becton, Dickinson and Company), Myriad Genetics, Hologic, Inc., Biocept, Inc., Thermo Fisher Scientific, Inc., Danaher.

Customization

Report customization along with purchase available upon request

Cancer Biopsy Sensor Market, By Category

Product

  • Kits and Consumables
  • Instruments and Services

Type

  • Tissue Biopsies
  • Liquid Biopsies

Region

  • North America
  • Europe
  • Asia-Pacific
  • South America
  • Middle East & Africa

Research Methodology of Market Research

To know more about the Research Methodology and other aspects of the research study, kindly get in touch with our .

Reasons to Purchase this Report

• Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors• Provision of market value (USD Billion) data for each segment and sub-segment• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled• Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players• The current as well as the future market outlook of the industry with respect to recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions• Includes in-depth analysis of the market of various perspectives through Porter’s five forces analysis• Provides insight into the market through Value Chain• Market dynamics scenario, along with growth opportunities of the market in the years to come• 6-month post-sales analyst support

Customization of the Report

• In case of any please connect with our sales team, who will ensure that your requirements are met.

Table of Content

To get a detailed Table of content/ Table of Figures/ Methodology Please contact our sales person at ( chris@marketinsightsresearch.com )

List Tables Figures

To get a detailed Table of content/ Table of Figures/ Methodology Please contact our sales person at ( chris@marketinsightsresearch.com )

FAQ'S

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@marketinsightsresearch.com

Within 24 to 48 hrs.

You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.